Dr. Lori Rudolph-Owen has served as the Chief Development Officer at Goldfinch Bio since 2020, after joining the company in 2018 as Senior Vice President of R&D Strategy and Operation. An accomplished C-Suite executive, she offers two decades of experience directing strategic portfolio planning and leadership, development operations and building talent for optimal organization growth in pharmaceutical and biotechnology R&D space. Previously, she was Vice President of Portfolio Management and Assessment at TESARO, Inc, and served in leadership roles at Pfizer, AMAG Pharmaceuticals, MGI Pharma (now Eisai), and Vertex. Dr. Rudolph-Owen holds a PhD in Cell Biology from the Vanderbilt University School of Medicine.